person · Reporting owner

Arbuckle Stuart A

Disclosed activity across 6 companies

Tapewire entity: 15072
SEC CIK: 0001557290

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
ALNYLAM PHARMACEUTICALS, INC.ALNY · Entity 3132	Director	May 20, 2026	May 22, 2026
Dare Bioscience, Inc.CERU · Entity 7799	Director	January 03, 2017	January 05, 2017
Praxis Precision Medicines, Inc.PRAX · Entity 3538	Director	June 10, 2026	June 12, 2026
RHYTHM PHARMACEUTICALS, INC.RYTM · Entity 3693	Director	June 23, 2026	June 25, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

ALNYLAM PHARMACEUTICALS, INC.

Report date May 20, 2026 · Filed May 22, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	671	Reported balance After 2026-05-20 transaction · row 1 1 source row Row 1 · 2026-05-20 · Grant · Acquired 671 · Balance 671 F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $298.48 · Expires 2036-05-20	Direct	1,441	Reported balance After 2026-05-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-05-20 · Grant · Acquired 1,441 · Balance 1,441 F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Filing footnotes · ownership attribution and instrument terms

F1: These shares are represented by restricted stock units (RSUs) granted under the Second Amended and Restated 2018 Stock Incentive Plan. Each RSU represents a contingent right to receive one share of common stock. The RSUs will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

F2: The stock option will vest in full upon the earlier of the first anniversary of the grant date and the date of any earlier retirement or resignation of the Reporting Person, provided such date of retirement or resignation occurs no more than 90 days prior to the first anniversary of the grant date.

Dare Bioscience, Inc.

Report date January 03, 2017 · Filed January 05, 2017

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	13,104	Reported balance After 2017-01-03 transaction · row 1 1 source row Row 1 · 2017-01-03 · Grant · Acquired 7,467 · Balance 13,104 F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017.

Filing footnotes · ownership attribution and instrument terms

F1: Consists of shares of common stock issued in lieu of cash retainers for board and committee service in accordance with an election of the reporting person under the company's non-employee director compensation program. The number of shares is equal to the amount of the cash retainers that would otherwise have been payable to the reporting person for the fourth fiscal quarter of 2016 divided by $0.77, the closing price of the company's common stock on the NASDAQ Global Market on January 3, 2017.

Praxis Precision Medicines, Inc.

Report date June 10, 2026 · Filed June 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,537	Reported balance After 2026-06-10 transaction · row 1 1 source row Row 1 · 2026-06-10 · Grant · Acquired 1,371 · Balance 2,537 F1: Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $240.66 · Expires 2036-06-10	Direct	648	Reported balance After 2026-06-10 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-10 · Grant · Acquired 648 · Balance 648 F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

Filing footnotes · ownership attribution and instrument terms

F1: Mr. Arbuckle was awarded 1,371 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. The restricted stock units vest in a single annual installment on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders. The restricted stock units may be settled only by delivering shares of the Issuer's common stock, and thus, the grant is being reported in Table 1 as allowed per SEC guidance.

F2: The shares subject to this option shall vest in twelve (12) equal monthly installments occurring on the 10th day of each month, with the first such installment occurring on July 10, 2026 and the final such installment occurring on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

RHYTHM PHARMACEUTICALS, INC.

Report date June 23, 2026 · Filed June 25, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	11,712	Reported balance After 2026-06-23 transaction · row 1 1 source row Row 1 · 2026-06-23 · Exercise / conversion · Acquired 4,712 · Balance 11,712 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-06-23 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-06-23 · Exercise / conversion · Disposed 4,712 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.
Restricted Stock UnitsSEC Table II · derivative / convertible security	Direct	2,324	Reported balance After 2026-06-24 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-06-24 · Grant · Acquired 2,324 · Balance 2,324 F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock. F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $107.55 · Expires 2036-06-23	Direct	3,691	Reported balance After 2026-06-24 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2026-06-24 · Grant · Acquired 3,691 · Balance 3,691 F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

Filing footnotes · ownership attribution and instrument terms

F1: Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

F2: The restricted stock units are fully vested. The restricted stock units have no expiration date.

F3: The options fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date.

F4: The restricted stock units fully vest upon the earlier of (i) June 24, 2027 or (ii) the day immediately prior to the date of the Issuer's next annual meeting of the stockholders to be held in 2027, subject to the Reporting Person's continued service on such vesting date. The restricted stock units have no expiration date.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

ImmunoGen, Inc.

Report date February 12, 2024 · Filed February 12, 2024

Section 16 reporting ended · disclosed 2024-02-12. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-02-12 transaction · row 1 1 source row Row 1 · 2024-02-12 · Disposition to issuer · Disposed 5,381 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger"). F2: At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").
Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-02-12 · Disposition to issuer · Disposed 13,090 · Balance 0 F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Deferred Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-02-12 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-12 · Disposition to issuer · Disposed 63,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.20 · Expires 2028-01-23	Direct	Reported balance After 2024-02-12 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-02-12 · Disposition to issuer · Disposed 4,167 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.21 · Expires 2028-06-20	Direct	Reported balance After 2024-02-12 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-02-12 · Disposition to issuer · Disposed 15,800 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.10 · Expires 2029-06-20	Direct	Reported balance After 2024-02-12 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-02-12 · Disposition to issuer · Disposed 18,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.56 · Expires 2030-06-17	Direct	Reported balance After 2024-02-12 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-02-12 · Disposition to issuer · Disposed 50,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.77 · Expires 2031-06-16	Direct	Reported balance After 2024-02-12 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.37 · Expires 2032-06-15	Direct	Reported balance After 2024-02-12 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2024-02-12 · Disposition to issuer · Disposed 44,000 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $17.72 · Expires 2033-06-14	Direct	Reported balance After 2024-02-12 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2024-02-12 · Disposition to issuer · Disposed 19,597 · Balance 0 F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

Filing footnotes · ownership attribution and instrument terms

F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated November 30, 2023, by and among the Issuer, AbbVie Inc., a Delaware corporation ("AbbVie"), Athene Subsidiary LLC, a Delaware limited liability company and wholly owned subsidiary of AbbVie ("Intermediate Sub"), and Athene Merger Sub Inc., a Massachusetts corporation and wholly owned subsidiary of Intermediate Sub ("Purchaser"), pursuant to which Purchaser merged with and into the Issuer with the Issuer continuing as the surviving corporation (the "Merger").

F2: At the effective time of the Merger (the "Effective Time"), each share of common stock, par value $.01 per share, of the Issuer (the "Common Stock"), that was issued and outstanding immediately prior to the Effective Time was converted into the right to receive an amount in cash equal to $31.26, without interest (the "Merger Consideration").

F3: Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit ("RSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such RSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such RSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F4: Pursuant to the Merger Agreement, at the Effective Time, each deferred share unit ("DSU") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such DSU, an amount in cash (less any applicable withholding taxes) equal to (i) the number of shares of Common Stock subject to such DSU immediately prior to the Effective Time, multiplied by (ii) the Merger Consideration.

F5: Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") granted prior to the date of the Merger Agreement that was outstanding immediately prior to the Effective Time was canceled, and the Reporting Person was entitled to receive (without interest), in consideration of the cancellation of such Stock Option, an amount in cash (less any applicable withholding taxes) equal to (i) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time, multiplied by (ii) the excess, if any, of the Merger Consideration over the applicable exercise price per share of Common Stock under such Stock Option.

VERTEX PHARMACEUTICALS INC / MA

Report date July 01, 2025 · Filed July 02, 2025

Section 16 reporting ended · disclosed 2025-07-02. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	63,368	Reported balance After 2025-07-01 transaction · row 1 1 source row Row 1 · 2025-07-01 · Tax withholding · Disposed 37,243 · Balance 63,368
Common StockSEC Table I · non-derivative	Indirect401(k)	140	Reported balance Holding disclosure · report date 2025-07-01 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 140

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 04, 2020 Filed May 6, 2020 20:38 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	640	$259.36	$165,990.40	Disclosure SEC source: 0001209191-20-027487 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,092 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $259.36 (range $258.85 to $259.74). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
May 04, 2020 Filed May 6, 2020 20:38 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,553	$86.52	$134,365.56	Disclosure SEC source: 0001209191-20-027487 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,732 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	632	$238.33	$150,624.56	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,179 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $238.33 (range $237.98 to $238.54). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	20	$236.88	$4,737.60	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,811 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	420	$236.36	$99,271.20	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,831 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $236.36 (range $235.69 to $236.65). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	540	$235.14	$126,975.60	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,251 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $235.14 (range $234.61 to $235.56). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	420	$234.08	$98,313.60	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,791 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $234.08 (range $233.57 to $234.44). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	360	$232.35	$83,646.00	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,211 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $232.35 (range $232.03 to $232.72). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	432	$230.85	$99,727.20	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,571 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $230.85 (range $230.51 to $231.30). Read SEC document
February 25, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	810	$229.78	$186,121.80	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,003 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $229.78 (range $229.21 to $230.14). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 24, 2020 Filed Feb 26, 2020 21:30 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	2,898	$239.23	$693,288.54	Disclosure SEC source: 0001209191-20-013020 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,813 Read SEC document
February 18, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	377	$245.76	$92,651.52	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,711 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $245.76 (range $245.54 to $245.90). Read SEC document
February 18, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	580	$245.04	$142,123.20	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,088 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $245.04 (range $244.52 to $245.44). Read SEC document
February 18, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	400	$243.76	$97,504.00	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,668 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.45 to $244.43). Read SEC document
February 18, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,011	$242.91	$245,582.01	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,068 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38). F4 · price: Open market sales reported on this line occurred at a weighted average price of $242.91 (range $242.43 to $243.42). Read SEC document
February 18, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	760	$242.08	$183,980.80	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,079 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $242.08 (range $241.41 to $242.38). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 17, 2020 Filed Feb 19, 2020 21:32 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	2,496	$241.50	$602,784.00	Disclosure SEC source: 0001209191-20-010537 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,839 Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	486	$248.62	$120,829.32	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,335 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $248.62 (range $248.47 to $248.90). Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,863	$247.91	$461,856.33	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,821 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $247.91 (range $247.44 to $248.43). Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,770	$246.76	$436,765.20	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,684 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $246.76 (range $246.43 to $247.29). Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	3,377	$245.93	$830,505.61	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,454 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $245.93 (range $245.37 to $246.28). Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	2,860	$244.99	$700,671.40	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,831 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $244.99 (range $244.37 to $245.36). Read SEC document
February 11, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	930	$243.76	$226,696.80	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,691 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $243.76 (range $243.29 to $244.28). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 10, 2020 Filed Feb 12, 2020 22:13 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Tax withholdingCommon Stock	8,942	$240.95	$2,154,574.90	Disclosure SEC source: 0001209191-20-008867 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,621 Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	1,223	$0.00 Strike: $155.57	$0.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · derivative · entry 13 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,783 Underlying: Common Stock · 1,223 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F11 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2018. Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	1,564	$0.00 Strike: $187.53	$0.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · derivative · entry 12 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,770 Underlying: Common Stock · 1,564 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	171	$242.47	$41,462.37	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 10 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,563 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	150	$241.08	$36,162.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,734 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F9 · price: Open market sales reported on this line occurred at a weighted average price of $241.08 (range $241.04 to $241.12). Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	230	$240.53	$55,321.90	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,884 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F8 · price: Open market sales reported on this line occurred at a weighted average price of $240.53 (range $240.40 to $240.60). Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	725	$239.47	$173,615.75	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,114 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $239.47 (range $239.11 to $240.04). Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,511	$238.71	$360,690.81	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,839 F4 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F5 · price: Open market sales reported on this line occurred at a weighted average price of $238.71 (range $238.07 to $239.05). F6 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,223	$155.57	$190,262.11	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 06, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,564	$187.53	$293,296.92	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,127 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 05, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	12,387	$0.00	$0.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,563 F3 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2021. Read SEC document
February 05, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	9,800	$0.00	$0.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,176 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/06/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020. The earned performance shares will vest in installments beginning on 02/24/2020. Read SEC document
February 05, 2020 Filed Feb 7, 2020 21:08 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	GrantCommon Stock	12,136	$0.00	$0.00	Disclosure SEC source: 0001209191-20-007477 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,376 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2017 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/05/2020 and the shares will vest on 02/10/2020. Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	1,554	$0.00 Strike: $86.52	$0.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · derivative · entry 13 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,213 Underlying: Common Stock · 1,554 shares Expires 2027-02-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F10 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/03/2017. Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	2,156	$0.00 Strike: $91.05	$0.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · derivative · entry 12 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,156 shares Expires 2026-02-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F9 · derivative.exercise_date: Fully vested. Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	540	$232.71	$125,663.40	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 9 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F7 · price: Open market sales reported on this line occurred at a weighted average price of $232.71 (range $232.50 to $232.94). Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	900	$231.87	$208,683.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 8 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,780 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F6 · price: Open market sales reported on this line occurred at a weighted average price of $231.87 (range $231.50 to $232.44). Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	1,300	$231.16	$300,508.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 7 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,680 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F5 · price: Open market sales reported on this line occurred at a weighted average price of $231.16 (range $230.48 to $231.47). Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	530	$229.99	$121,894.70	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 6 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,980 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F4 · price: Open market sales reported on this line occurred at a weighted average price of $229.99 (range $229.48 to $230.46). Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	440	$228.90	$100,716.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 5 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,510 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. F2 · price: Open market sales reported on this line occurred at a weighted average price of $228.90 (range $228.37 to $229.11). F3 · price: Mr. Arbuckle undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	1,554	$86.52	$134,452.08	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,950 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
February 03, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	2,156	$91.05	$196,303.80	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 3 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
January 31, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	4,692	$0.00 Strike: $187.53	$0.00	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · derivative · entry 11 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,334 Underlying: Common Stock · 4,692 shares Expires 2029-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F8 · derivative.exercise_date: The option vests in 16 quarterly installments from 02/06/2019. Read SEC document
January 31, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	4,692	$238.65	$1,119,745.80	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 2 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document
January 31, 2020 Filed Feb 4, 2020 21:10 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionCommon Stock	4,692	$187.53	$879,890.76	Disclosure SEC source: 0001209191-20-006279 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP, Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,932 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
November 15, 2019 Filed Nov 19, 2019 21:09 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	SaleCommon Stock	19	$205.95	$3,913.05	Disclosure SEC source: 0001209191-19-057126 · doc4.xml · nonDerivative · entry 1 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,240 F1 · kind: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1. Read SEC document
November 13, 2019 Filed Nov 15, 2019 21:03 UTC	VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875	Exercise / conversionStock Option (Right to Buy) · Derivative	8,560	$0.00 Strike: $155.57	$0.00	Disclosure SEC source: 0001209191-19-056706 · doc4.xml · derivative · entry 4 Arbuckle Stuart A · CIK 0001557290 · EVP\Chief Commercial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,006 Underlying: Common Stock · 8,560 shares Expires 2028-02-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: The option vests in 16 quarterly installments from 2/6/2018. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.